A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

Completed · Phase 4

Conditions studied: Secondary Hyperparathyroidism

In brief

Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.

Key facts

Study ID
NCT00463021
Run by
Genzyme, a Sanofi Company
People needed
36
Starts
2007-04-01
Expected to finish
2007-12-01
Last updated by the study team
2015-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.